FDA Grants Fast Track Status to Celsion’s GEN-1 for Advanced Cancer

FDA Grants Fast Track Status to Celsion’s GEN-1 for Advanced Cancer

287954

FDA Grants Fast Track Status to Celsion’s GEN-1 for Advanced Cancer

Celsion‘s immunotherapy candidate, GEN-1, has received fast track designation from the U.S. Food and Drug Administration (FDA) for advanced ovarian cancer. This designation helps speed the approval of potential medicines that address unmet medical needs in serious or life-threatening conditions. It grants greater access to FDA input throughout the regulatory process and makes GEN-1 eligible for accelerated approval and priority review, provided it meets certain criteria. “Fast Track designation is an important step in developing…

You must be logged in to read/download the full post.